RESUMEN
Coronavirus disease 2019 (COVID-19) vaccine administration started in February 2021 in Japan. As of December 2021, approximately 75% of the population aged ≥12 years had received two doses of vaccine. We conducted a study to investigate vasovagal reactions (VVR) after COVID-19 vaccination using data on adverse events following immunization. The crude reporting rate of VVR (cases/1,000,000 doses) after vaccination was 9.6 in all age groups combined, and was more frequent in the younger age groups: 28.6 and 37.2 in individuals aged 10-19 years and 20-29 years, respectively. In individuals aged 10-29 years, the rate was similar in males and females (33.0 and 34.2, respectively, p = 0.53); but was higher after dose 1 than after dose 2 (57.4 and 8.8, respectively, p < 0.001). Based on these results, caution needs to be exercised when vaccinating adolescents and young adults, especially with dose 1 of COVID-19 vaccines.
Asunto(s)
Vacunas contra la COVID-19 , COVID-19 , Síncope Vasovagal , Adolescente , Adulto , COVID-19/prevención & control , Vacunas contra la COVID-19/efectos adversos , Niño , Femenino , Humanos , Japón/epidemiología , Masculino , Síncope Vasovagal/inducido químicamente , Vacunación/efectos adversos , Adulto JovenRESUMEN
Coronavirus disease 2019 (COVID-19) has become a pandemic, and vaccines remain the only effective tools available for ending it. However, their side effects, such as syncope, which mimics sudden cardiac death, are serious concerns. We herein report 6 cases of delayed vasovagal syncope and presyncope (VVR) caused by COVID-19 vaccination among 25,530 COVID-19 patients. The prevalence of delayed VVR due to COVID-19 vaccination was 0.026%. In addition, no delayed VVR was found among 17,386 patients who received the influenza vaccine. Delayed VVR is likely to be overlooked if medical staff are not aware of this symptom. This report provides significant information regarding effects of COVID-19 vaccination.
Asunto(s)
Vacunas contra la COVID-19 , COVID-19 , Síncope Vasovagal , COVID-19/prevención & control , Vacunas contra la COVID-19/efectos adversos , Humanos , Síncope/inducido químicamente , Síncope Vasovagal/inducido químicamente , Vacunación/efectos adversosRESUMEN
AIMS: The aim of our study was to evaluate the prevalence and clinical predictors of cardioinhibitory (CI) responses with asystole at the nitroglycerin (NTG)-potentiated head-up tilt test (HUTT) in patients with a history of syncope admitted to a tertiary referral syncope unit. METHODS: We retrospectively evaluated all consecutive patients who underwent NTG-potentiated HUTT for suspected reflex syncope at our institution from March 1 2017 to May 1 2020. The prevalence of HUTT-induced CI syncope was assessed. Univariate and multivariate analyses were performed to test the association of asystolic response to HUTT with a set of clinical covariates. RESULTS: We enrolled 1285 patients (45 ± 19.1 years; 49.6% male); 368 (28.6%) showed HUTT-induced CI response with asystole. A multivariate analysis revealed that the following factors were independently associated with HUTT-induced CI syncope: male sex (OR 1.48; ConInt 1.14-1.92; P = 0.003), smoking (OR 2.22; ConInt 1.56-3.115; P < 0.001), traumatic syncope (OR: 2.81; ConInt 1.79-4.42; P < 0.001), situational syncope (OR 0.45; ConInt 0.27-0.73; P = 0.002), and the use of diuretics (OR 9.94; ConInt 3.83-25.76; P < 0.001). CONCLUSIONS: The cardioinhibitory syncope with asystole induced by NTG-potentiated HUTT is more frequent than previously reported. The male gender, smoking habit, history of traumatic syncope, and use of diuretics were independent predictors of HUTT-induced CI responses. Conversely, the history of situational syncope seems to reduce this probability.
Asunto(s)
Paro Cardíaco , Síncope Vasovagal , Diuréticos , Femenino , Paro Cardíaco/inducido químicamente , Paro Cardíaco/diagnóstico , Paro Cardíaco/epidemiología , Humanos , Masculino , Nitroglicerina/efectos adversos , Prevalencia , Estudios Retrospectivos , Síncope/inducido químicamente , Síncope/diagnóstico , Síncope/epidemiología , Síncope Vasovagal/inducido químicamente , Síncope Vasovagal/diagnóstico , Síncope Vasovagal/epidemiología , Pruebas de Mesa InclinadaRESUMEN
OBJECTIVE: This pharmacovigilance-based survey was aimed at determining the prevalence of, and association between, radiopharmaceuticals and adverse reactions to radiopharmaceuticals from 1975 to 2017 in Japan. METHODS: The Subcommittee for Safety Issues of Radiopharmaceuticals of the Japan Radioisotope Association's Medical Science and Pharmaceutical Committee mailed a form for reporting adverse reactions to radiopharmaceuticals to all institutes performing nuclear medicine examinations in Japan. This investigation included adverse reactions to diagnostic radiopharmaceuticals labeled with both single-photon- and positron-emitting radionuclides and therapeutic sodium iodide labeled with 131I. Each institute returned the reporting form to the subcommittee each time an adverse reaction occurred. RESULTS: Replies were obtained from 75% of the institutions. In total, 1099 adverse reactions were reported from 46,645,580 radiopharmaceutical administrations, giving a prevalence of 2.4 adverse reactions per 100,000 administrations (95% confidence interval 2.2-2.5). Adverse reactions were most frequently observed for 131I-iodomethylnorcholesterol (230.1/105 administrations), followed by 131I-HSA (76.3/105 administrations), 131I-sodium iodohippurate (31.2/105 administrations), and 99mTc-DTPA (12.0/105 administrations). Comparison of adverse reactions between before and after 1997 revealed that prevalence dropped from 3.7/105 administrations (95% confidence interval 3.5-4.1) to 1.5/105 administrations (95% confidence interval 1.4-1.6). During the study period, vasovagal reactions accounted for 50.3% of adverse reactions, fever for 7.5%, allergic reactions for 25.7%, and other for 16.5%; 3.7% of all adverse reactions were considered severe but none were lethal. A definite, probable, possible, less likely, and uncertain causal relationship with radiopharmaceuticals was observed in 13.1%, 33.7%, 39.9%, 6.2%, and 7.1% of adverse reactions, respectively. CONCLUSIONS: These results suggest that nuclear medicine staff must be aware of the possibility of adverse reactions from radiopharmaceuticals, despite their rarity.
Asunto(s)
Radiofármacos/efectos adversos , Hipersensibilidad a las Drogas , Fiebre/inducido químicamente , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Radioisótopos de Yodo/administración & dosificación , Radioisótopos de Yodo/efectos adversos , Japón , Medicina Nuclear , Prevalencia , Cintigrafía/efectos adversos , Radiofármacos/administración & dosificación , Índice de Severidad de la Enfermedad , Encuestas y Cuestionarios , Síncope Vasovagal/inducido químicamente , Pentetato de Tecnecio Tc 99m/administración & dosificación , Pentetato de Tecnecio Tc 99m/efectos adversosRESUMEN
La infección por el virus de la hepatitis C (VHC) es un problema de salud pública1. En el año 2015 se comercializaron en España nuevos fármacos antivirales de acción directa (AAD) capaces de eliminar de forma sostenida la replicación viral en más del 90% de los pacientes infectados2. Los fármacos AAD tienen un excelente perfil de seguridad y la duración del tratamiento está limitada a 8, 12 ó 24 semanas en función de una serie de parámetros3,4. Los profesionales sanitarios tienen que trabajar en equipo para seleccionar el tratamiento más adecuado para cada paciente teniendo en cuenta su situación clínica, sus comorbilidades y los tratamientos concomitantes. En 2015 la existencia de pacientes con infección por VIH coinfectados con VHC era de aproximadamente un 20%5 haciéndose imprescindible escoger el plan terapéutico con mejor perfil de interacciones. Se describe el caso de un paciente coinfectado con VIH y VHC que presenta una reacción adversa (RA), un síncope vagal, tras la primera administración de sofosbuvir/ledipasvir y que se repite tras la segunda administración, descartándose este tratamiento definitivamente
Infection with the hepatitis C virus (HCV) is a public health problem1. In 2015, new direct-acting antiviral drugs (ADA) were commercialized in Spain, capable of eliminating the sustained viral replication in more than 90% of infected patients2. AAD drugs have an excellent safety profile and the duration of treatment is limited to 8, 12 or 24 weeks depending on a series of parameters3,4. Health professionals have to work as a team to select the most appropriate treatment for each patient taking into account their clinical situation, comorbidities and concomitant treatments. In 2015, the existence of patients with HIV infection coinfected with HCV was approximately 20%5, making it essential to choose the therapeutic plan with the best interaction profile. We describe the case of a patient coinfected with HIV and HCV that presents an adverse reaction (RA), a vagal syncope, to the first administration of sofosbuvir/ledipasvir and that is repeated to the second administration, ruling out this treatment definitively
Asunto(s)
Humanos , Masculino , Persona de Mediana Edad , Síncope Vasovagal/inducido químicamente , Síncope Vasovagal/diagnóstico , Hepatitis C Crónica/complicaciones , Hepatitis C Crónica/tratamiento farmacológico , Infecciones por VIH/complicaciones , Infecciones por VIH/tratamiento farmacológico , Antivirales/efectos adversos , Antivirales/uso terapéutico , Fármacos Anti-VIH/uso terapéuticoRESUMEN
A 26-year-old woman with a history of feeling nauseated during dental local anesthesia presented to our clinic for tooth extraction under intravenous sedation. Although she had experienced episodes of neurally-mediated syncope, her symptoms were controlled well with drug therapy, stopped 3 years earlier. No syncope episodes developed over the previous 2 years. Tooth extraction was performed under intravenous sedation without incident. When she was returned to a sitting position after being roused, convulsion, loss of consciousness, and cardiac arrest developed. One week later, similar symptoms occurred immediately after suture removal. We suspect that the change in body position triggered these episodes. It is important to avoid abrupt changes in body position and any other triggers and to administer preventive drugs in patients at high risk of syncope.
Asunto(s)
Anestesia Dental , Paro Cardíaco , Síncope Vasovagal , Adulto , Anestesia Dental/efectos adversos , Electrocardiografía , Femenino , Paro Cardíaco/inducido químicamente , Humanos , Síncope , Síncope Vasovagal/inducido químicamenteRESUMEN
PURPOSE: Individuals predisposed to vasovagal syncope may have different autonomic nervous system control mechanisms from those without predisposition to vasovagal events. To test this hypothesis, we investigated different sympathetic responses in a canine model of vasovagal syncope. METHODS: Left thoracotomy was performed on 20 mongrel dogs. The heart was exposed and a bolus of veratridine (15 µg/kg), a neurotoxin which prevents the inactivation of sodium ion channels, was injected into the left atrium to induce a Bezold-Jarisch reflex-mediated vasovagal event, characterized by bradycardia, decreased inotropism, and hypotension. Electrocardiogram and blood pressure were continuously monitored. Neural activity was recorded from the left stellate ganglion. Plasma norepinephrine and acetylcholine levels were measured 30 s before and 30 s after veratridine injection. RESULTS: Veratridine resulted in rapid decreases in heart rate and blood pressure in all dogs, accompanied by increases in both norepinephrine and acetylcholine. Two types of neural activity (high-amplitude spike discharge activity and low-amplitude burst discharge activity) were recorded from the left stellate ganglion. Veratridine induced high-frequency spike discharge activity in some dogs (Group A), whereas spike discharge activity was scarce and relatively unresponsive to veratridine in the remaining dogs (Group B). Dogs in Group A had higher plasma norepinephrine levels (111.63 ± 15.1 vs. 48.11 ± 33.81 ng/l, p = 0.002) and less intense drops in heart rate (- 37 ± 24 vs. - 84 ± 28 bpm, p = 0.001) and blood pressure (systolic blood pressure, - 18 ± 15 vs. - 37 ± 13 mmHg, p = 0.009; diastolic blood pressure, - 26 ± 13 vs. - 45 ± 13 mmHg, p = 0.005) compared to dogs in Group B. Similarly, heart rate post-veratridine was higher (102 ± 23 vs. 69 ± 22 bpm, p = 0.004), the veratridine-induced longest RR interval was shorter (0.7 [0.5-0.8] vs. 1.2 [1.1-3.5] s, p < 0.001) and the diastolic and mean arterial pressures post-veratridine were higher (all p < 0.05) in dogs in Group A compared to those in Group B. CONCLUSIONS: Distinct sympathetic activation as represented by left stellate ganglion high-frequency spike discharge activity protected against bradycardia and hypotension in a canine model of vasovagal syncope. Our findings may have therapeutic implications.
Asunto(s)
Sistema Nervioso Simpático/fisiopatología , Síncope Vasovagal/fisiopatología , Acetilcolina/sangre , Animales , Presión Arterial , Presión Sanguínea , Perros , Electrocardiografía , Frecuencia Cardíaca , Hipotensión/fisiopatología , Masculino , Contracción Miocárdica , Norepinefrina/sangre , Bloqueadores de los Canales de Sodio , Ganglio Estrellado/fisiopatología , Síncope Vasovagal/inducido químicamente , VeratridinaRESUMEN
Adverse reactions to iodinated and gadolinium-based contrast agents occur at an incidence of less than 1%. Although the exact pathophysiologic mechanisms are not completely understood, the treatment regimens are well accepted. Skin testing may be helpful in patients with a history of severe allergiclike reaction to aid in the selection of alternative contrast agents. Premedication should only be used for a history of allergiclike reaction. Imaging team members should be familiar with signs and symptoms of contrast reactions to allow for prompt assessment and treatment. A plan of action should be in place for contrast reactions and rehearsed regularly.
Asunto(s)
Medios de Contraste/efectos adversos , Hipersensibilidad a las Drogas/terapia , Hipertensión/terapia , Edema Pulmonar/terapia , Síncope Vasovagal/terapia , Corticoesteroides/uso terapéutico , Antihipertensivos/uso terapéutico , Diuréticos/uso terapéutico , Hipersensibilidad a las Drogas/etiología , Fluidoterapia/métodos , Antagonistas de los Receptores Histamínicos/uso terapéutico , Humanos , Hipertensión/inducido químicamente , Nitroglicerina/uso terapéutico , Terapia por Inhalación de Oxígeno/métodos , Edema Pulmonar/inducido químicamente , Factores de Riesgo , Síncope Vasovagal/inducido químicamente , Vasodilatadores/uso terapéuticoRESUMEN
INTRODUCTION: Increased adrenergic tone might be an additional trigger of orthostatic stress of vasovagal syncope (VVS). Exercise before standing might provide increased sensitivity compared to standing using a sublingual nitroglycerines protocol during tilt table testing. The aim of this study was to evaluate the diagnostic value of treadmill testing before standing with nitroglycerin administration. METHODS AND RESULTS: A total of 36 patients with syncope or presyncope were enrolled for the test. VVS was confirmed in 29 patients according to the Calgary Score (≥ -2), including 20 patients who were likely to have typical (classical) VVS. All 36 subjects were subjected to a novel provocation test consisting of treadmill test using the Bruce protocol followed by standing with administration of 300 µg sublingual nitroglycerin. Consequently, syncope or presyncope occurred in 22 patients of the 36 patients. The sensitivity and a specificity of the test for Calgary score based VVS was 82.7% and 85.75%, respectively. Reproducibility rate for typical VVS was 90% (18 of 20). In all symptomatic patients, systolic blood pressure dropped to < 90 mmHg and symptom occurred a mean of 6.7 ± 2.3 minutes after the nitroglycerine administration. No patient required anticholinergics injection to restore vital signs. CONCLUSIONS: Treadmill test with administration of sublingual nitroglycerines might be safely used to reproduce syncope in patients with VVS. More clinical experience and confirmation are needed to validate this protocol.
Asunto(s)
Prueba de Esfuerzo , Nitroglicerina/efectos adversos , Síncope Vasovagal/diagnóstico , Síncope Vasovagal/fisiopatología , Administración Sublingual , Adulto , Femenino , Humanos , Masculino , Persona de Mediana Edad , Nitroglicerina/administración & dosificación , Síncope Vasovagal/inducido químicamenteRESUMEN
OBJECTIVES: Most elderly patients affected by reflex vasodepressor syncope take one or more hypotensive drugs. The role of these drugs in causing syncope has not yet been established. We hypothesised that recurrence of syncope and presyncope can be reduced by discontinuing/reducing vasoactive therapy without increasing the risk of cardiovascular and neurological events. METHODS: This randomised, parallel, prospective, trial was conducted from January 2014 to March 2016 in four general hospitals. Of 328 initially screened participants, 58 patients (mean (SD) age 74±11â years) affected by vasodepressor reflex syncope, which was reproduced by tilt testing (n=54) or carotid sinus massage (n=4), were randomised to stop/reduce vasoactive therapy or to continue it. Primary end point was recurrence of syncope, presyncope or adverse events (defined as stroke, cerebral transient ischaemic attacks, worsening heart failure, myocardial infarction). RESULTS: Of 58 patients who were randomised, 55 completed the trial. After 1â month, systolic blood pressure was significantly higher in the 'stop/reduce' group than in the 'continue' group, in both supine (141±13â mmâ Hg vs 128±14â mmâ Hg; p=0.004) and standing (133±13â mmâ Hg vs 122±15â mmâ Hg; p=0.02) positions. During a mean follow-up of 13±7â months, the primary combined end point occurred in seven 'stop/reduce' patients (23%): three had syncope, three had presyncope and one had heart failure. Conversely, it occurred in 13 'continue' patients (54%): 10 had syncope, 2 had presyncope and 1 had cerebral transient ischaemic attack. The log-rank p value was 0.02 and the HR was 0.37 (95% CI 0.15 to 0.91). CONCLUSIONS: Recurrence of syncope and presyncope can be reduced by discontinuing/reducing vasoactive therapy in most elderly patients affected by reflex vasodepressor syncope. TRIAL REGISTRATION NUMBER: NCT01509534; EudraCT2013-004364-63; Results.
Asunto(s)
Presión Sanguínea/efectos de los fármacos , Sistema Cardiovascular/inervación , Reflejo/efectos de los fármacos , Síncope Vasovagal/prevención & control , Vasoconstrictores/administración & dosificación , Vasoconstrictores/efectos adversos , Anciano , Anciano de 80 o más Años , Esquema de Medicación , Femenino , Hospitales Generales , Humanos , Italia , Masculino , Persona de Mediana Edad , Postura , Estudios Prospectivos , Recurrencia , Síncope Vasovagal/inducido químicamente , Síncope Vasovagal/diagnóstico , Síncope Vasovagal/fisiopatología , Pruebas de Mesa Inclinada , Resultado del TratamientoRESUMEN
BACKGROUND: Head-up tilt test (HUT) has been used for nearly 30 years for diagnosing vasovagal syncope (VVS) and was enhanced by sublingual nitroglycerin (glyceryl trinitrate [GTN]) challenge in the 1990s. OBJECTIVE: The purpose of this study was to explore neuroendocrine differences between spontaneous and drug-induced HUT positivity. METHODS: Two hundred eighty-eight patients (41.3% male, age 49 ± 21 years) with either positive passive (n = 60 [20.8%], age 38 ± 17 years) or GTN-enhanced HUT (n = 228, age 51 ± 21 years) were assessed. Beat-to-beat hemodynamic data, plasma epinephrine, plasma norepinephrine, plasma renin, C-terminal pro-arginine vasopressin (CT-proAVP), C-terminal endothelin-1, and mid-regional fragment of pro-atrial natriuretic peptide were measured resting supine and after 3 minutes of HUT. In multivariate-adjusted regression analyses controlling for age and gender, clinical, neuroendocrine, and hemodynamic parameters were compared between spontaneous and GTN-mediated positive tests. RESULTS: Patients with spontaneous VVS reported more syncope compared to those with GTN-mediated VVS (median interquartile range 6 [17] vs 4 [6], P = .002). There was no difference in resting concentrations of neurohormones between the 2 groups. However, after 3 minutes of HUT, those who later developed spontaneous VVS demonstrated higher levels of CT-proAVP (59.5 ± 137 vs 6.9 ± 4.6, P <0.001) and epinephrine (0.57 ± 1.43 vs 0.23 ± 0.19, P = .003), and lower blood pressure (119/73 vs 139/81 mm Hg, P <.001). Asystole during VVS was more common in the spontaneous VVS group (35% vs 17.5%, P = .016). CONCLUSION: Patients with spontaneous VVS on HUT reported more syncopal events than those with drug-potentiated positive HUT, but both groups shared similar supine neuroendocrine profiles. However, spontaneous VVS during HUT is characterized by lower blood pressure, pronounced increases in epinephrine and vasopressin during early HUT phase, and higher frequency of reflex asystole.
Asunto(s)
Electrocardiografía/efectos de los fármacos , Sistemas Neurosecretores/fisiopatología , Nitroglicerina/administración & dosificación , Reflejo/efectos de los fármacos , Síncope Vasovagal/fisiopatología , Pruebas de Mesa Inclinada , Administración Sublingual , Adulto , Femenino , Frecuencia Cardíaca , Humanos , Masculino , Persona de Mediana Edad , Síncope Vasovagal/inducido químicamente , Síncope Vasovagal/diagnóstico , Vasodilatadores/administración & dosificaciónRESUMEN
BACKGROUND: Prolonged ventricular asystole is a rare vagal reaction caused by hydrocodone use. Sinus bradycardia is a characteristic presentation of the vasovagal response; examples of other presentations include arrest or atrioventricular block. Physicians need to be aware of ventricular asystole due to vagally-mediated atrioventricular block caused by hydrocodone or other opiates. CASE REPORT: We present a case of prolonged ventricular asystole in a young patient due to a vasovagal reaction caused by the hydrocodone found in the hydrocodone/acetaminophen combination. CONCLUSIONS: Ventricular asystole can be a rare complication of hydrocodone found in hydrocodone/acetaminophen. Physicians need to be aware of this adverse effect, rather then resorting to expensive diagnostic interventions.
Asunto(s)
Electrocardiografía , Paro Cardíaco/inducido químicamente , Ventrículos Cardíacos/fisiopatología , Hidrocodona/efectos adversos , Síncope Vasovagal/inducido químicamente , Analgésicos Opioides/efectos adversos , Analgésicos Opioides/uso terapéutico , Femenino , Paro Cardíaco/diagnóstico , Ventrículos Cardíacos/efectos de los fármacos , Humanos , Hidrocodona/uso terapéutico , Persona de Mediana Edad , Síncope Vasovagal/diagnóstico , Síncope Vasovagal/fisiopatologíaRESUMEN
OBJECTIVES: To evaluate whether trainee involvement (resident and fellow) during transforaminal epidural steroid injections (TFESI) results in greater rates of vasovagal reactions. DESIGN: Retrospective study on consecutive patients. SETTING: Single academic medical center with multiple attending physicians and trainees. PARTICIPANTS: A total of 2642 consecutive subjects undergoing 4482 TFESI were analyzed from March 8, 2004, to January 30, 2009. MAIN OUTCOME MEASURES: The Pearson χ(2) test was used to determine the relationship between vasovagal reactions and level of trainee involvement. RESULTS: A total of 4482 TFESIs were performed, with 157 (3.5%) of procedures complicated by a vasovagal reaction. An attending physician performed 2884 (64.3%) procedures without trainee involvement, with only 79 (2.7%) vasovagal reaction noted. A fellow was involved in 723 (16.1%) procedures, with 30 (4.1%) noted to have a vasovagal reaction. A resident was involved in 875 (19.5%) procedures, with 48 (5.5%) having a vasovagal reaction. Overall, trainees were involved in 1598 (35.7%) cases, of which 78 (4.9%) were complicated by vasovagal reaction. When a trainee was involved in the case, there was a greater incidence of vasovagal episodes (P < .001, χ(2) = 16.047). Although there was a trend towards greater vasovagal rates with residents over fellows, this did not reach statistical difference. CONCLUSIONS: Vasovagal reactions can occur with spine injection procedures and may result in premature procedure termination or other adverse events. Although this retrospective study has significant potential for bias, it appears that trainee involvement in a TFESI is associated with a greater incidence of vasovagal reaction (P < .001, χ(2) = 16.047).
Asunto(s)
Internado y Residencia/métodos , Dolor de la Región Lumbar/tratamiento farmacológico , Esteroides/efectos adversos , Síncope Vasovagal/epidemiología , Nervio Vago/efectos de los fármacos , Centros Médicos Académicos , Anciano , Femenino , Fluoroscopía/métodos , Estudios de Seguimiento , Humanos , Incidencia , Inyecciones Epidurales/efectos adversos , Masculino , Estudios Retrospectivos , Esteroides/administración & dosificación , Síncope Vasovagal/inducido químicamente , Estados Unidos/epidemiologíaRESUMEN
We report syncope and bradycardia in an 11-year-old girl following administration of intranasal dexmedetomidine for sedation for a voiding cystourethrogram. Following successful completion of VCUG and a 60-min recovery period, the patient's level of consciousness and vital signs returned to presedation levels. Upon leaving the sedation area, the patient collapsed, with no apparent inciting event. The patient quickly regained consciousness and no injury occurred. The primary abnormality found was persistent bradycardia, and she was admitted to the hospital for telemetric observation. The bradycardia lasted ~2 h, and further cardiac workup revealed no underlying abnormality. Unanticipated and previously unreported outcomes may be witnessed as we expand the use of certain sedatives to alternative routes of administration.
Asunto(s)
Bradicardia/inducido químicamente , Sedación Consciente/efectos adversos , Dexmedetomidina/efectos adversos , Hipnóticos y Sedantes/efectos adversos , Síncope Vasovagal/inducido químicamente , Administración Intranasal , Niño , Dexmedetomidina/administración & dosificación , Femenino , Frecuencia Cardíaca/efectos de los fármacos , Humanos , Hipnóticos y Sedantes/administración & dosificación , Procedimientos Quirúrgicos UrológicosRESUMEN
INTRODUCTION: Escitalopram is rarely associated with prolongation of the QTc interval; however, there are no reported cases of QRS complex widening associated with escitalopram overdose. We report a case of a patient who presented with both QRS complex widening and QTc interval prolongation after an escitalopram overdose. CASE: A 16-year-old girl presented to the emergency department after ingestion of escitalopram, tramadol/acetaminophen, and hydrocodone/acetaminophen. Laboratory results were significant for 4-hour acetaminophen 21.1 µg/mL. Serum electrolytes including potassium, magnesium, and calcium were all normal. Initial electrocardiogram (ECG) revealed a widened QRS with an incomplete right bundle branch pattern. After administration of 100-mEq sodium bicarbonate, a repeat ECG revealed narrowing of the QRS complex and a prolonged QTc interval. Magnesium sulfate 2 g intravenous and sodium bicarbonate drip were initiated. A repeat ECG, 1 hour after the second, revealed normalization of the QRS complex and QTc interval. DISCUSSION: Prolongation of the QTc interval is an expected effect of escitalopram. Both escitalopram and citalopram are metabolized to the cardiotoxic metabolite S-didesmethylcitalopram and didesmethylcitalopram, respectively, which have been implicated in numerous cardiac abnormalities including widening of the QRS complex. Although never previously described with escitalopram, this mechanism provides a reasonable explanation for the QRS complex widening and incomplete right bundle branch block that occurred in our patient. CONCLUSIONS: Both QRS complex widening and QTc interval prolongation should be monitored in cases of escitalopram and citalopram overdoses.
Asunto(s)
Bloqueo de Rama/inducido químicamente , Citalopram/envenenamiento , Electrocardiografía/efectos de los fármacos , Sistema de Conducción Cardíaco/efectos de los fármacos , Canales de Sodio/efectos de los fármacos , Acetaminofén/envenenamiento , Adolescente , Antídotos/administración & dosificación , Antídotos/uso terapéutico , Bradicardia/inducido químicamente , Bradicardia/tratamiento farmacológico , Bloqueo de Rama/sangre , Bloqueo de Rama/tratamiento farmacológico , Bloqueo de Rama/fisiopatología , Citalopram/análogos & derivados , Citalopram/sangre , Citalopram/farmacocinética , Citalopram/farmacología , Citalopram/toxicidad , Canales de Potasio de Tipo Rectificador Tardío/efectos de los fármacos , Quimioterapia Combinada , Urgencias Médicas , Femenino , Humanos , Hidrocodona/envenenamiento , Síndrome de QT Prolongado/inducido químicamente , Sulfato de Magnesio/administración & dosificación , Sulfato de Magnesio/uso terapéutico , Bicarbonato de Sodio/administración & dosificación , Bicarbonato de Sodio/uso terapéutico , Intento de Suicidio , Síncope Vasovagal/inducido químicamente , Tramadol/envenenamientoRESUMEN
OBJECTIVE: To assess frequency of sedation in transforaminal epidural steroid injections (TFESI) and to analyze patient dissatisfaction and vasovagal rates. DESIGN: Retrospective audit over a 6-year period, January 1, 2006-December 31, 2011. SETTING: Single academic center radiology pain management practice. SUBJECTS: Four thousand four hundred thirty-two patients undergoing 6,878 consecutive TFESI. OUTCOME MEASURES: Frequency of sedation for TFESI was assessed. Vasovagal and patient dissatisfaction rates were assessed, the latter by patients' responses to two follow-up survey questions at 2 weeks postprocedure. RESULTS: Six thousand eight hundred seventy-eight TFESI were performed, of which only 0.1% (N = 7) were performed with sedation. Only 0.4% (N = 28) of TFESI were complicated by vasovagal reaction. Seventy-two percent (N = 4,980) of nonsedated patients responded to the survey. Overall medical care in the nonsedated was rated as: excellent 51%, very good 30%, good 15%, fair 3%, and poor 1%. Ninety-five percent confidence interval (CI) for the 3.9% of the nonsedated patients who rated their care at best "fair" was (3.3, 4.4%). Likelihood of referring friends/family members in nonsedated patients was: definitely 53%, probably 28%, uncertain 16%, probably not 3%, definitely not 0.2%. Ninety-five percent CI for the 3.2% of the nonsedated patients who would at best "probably not refer" their friends/family was (2.7, 3.7%). CONCLUSIONS: In our radiology pain management practice, sedation was rarely utilized for TFESI. A small minority of nonsedated patients rated their care at best fair and would at best probably not refer friends/family members. TFESI can be performed without sedation with low patient dissatisfaction and low vasovagal rates.
Asunto(s)
Sedación Consciente/métodos , Espacio Epidural/fisiología , Satisfacción del Paciente , Esteroides/administración & dosificación , Nervio Vago/efectos de los fármacos , Anciano , Femenino , Hemodinámica/efectos de los fármacos , Humanos , Inyecciones Epidurales , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Esteroides/efectos adversos , Sistema Nervioso Simpático/efectos de los fármacos , Síncope Vasovagal/inducido químicamente , Síncope Vasovagal/epidemiología , Resultado del TratamientoRESUMEN
BACKGROUND: The aim of the study was to assess the main determinant of the fall in blood pressure (BP) responsible for the head-up tilt testing-induced syncope. METHODS AND RESULTS: The study involved 200 patients (mean age 42 ± 3; 81 male) with syncope of unknown origin after the first evaluation. According to the response to the diagnostic tilt test, the population study was divided into four groups: Group I with mixed vasovagal syncope; Group II with cardioinhibitory syncope; Group III with vasodepressive syncope; Group IV: 40 patients with clinical syncope but no tilt-induced syncope. Finger arterial BP (Portapres, TNO, Amsterdam, the Netherlands) was recorded during tilt testing. Left ventricular stroke volume (SV), cardiac output (CO), and total peripheral resistance (TPR) were computed from the pressure pulsations (Modelflow, TNO, Amsterdam, the Netherlands). During syncopal phase, the TPR decreased significantly in Group III, and increased in Group I and in Group II. CO decreased in Group I and in Group II and did not change significantly in Group III. SV decreased significantly in all groups. CONCLUSIONS: Our data showed that the arterial system appears to be the main determinant of the BP fall in vasodepressive vasovagal syncope; while the impaired constrictive response of the venous system, leading to reduced venous return to the heart, appears to be the main determinant of BP fall in mixed and cardioinhibitory vasovagal syncope.
Asunto(s)
Hipotensión/fisiopatología , Nitroglicerina , Síncope Vasovagal/fisiopatología , Pruebas de Mesa Inclinada , Adulto , Presión Sanguínea , Femenino , Humanos , Hipotensión/diagnóstico , Masculino , Síncope Vasovagal/inducido químicamente , VasodilatadoresRESUMEN
The cardiovascular safety profile of dapoxetine, a novel selective serotonin reuptake inhibitor (SSRI) developed as an on-demand oral treatment for premature ejaculation (PE) in men, is evaluated. The cardiovascular assessment of dapoxetine was conducted throughout all stages of drug development, with findings from preclinical safety pharmacology studies, phase I clinical pharmacology studies investigating the effect of dapoxetine on QT/corrected QT (QTc) intervals in healthy men, and phase III, randomized, placebo-controlled studies evaluating the safety (and efficacy) of the drug. Preclinical safety pharmacology studies did not suggest an adverse electrophysiologic or hemodynamic effect with concentrations of dapoxetine up to 2-fold greater than recommended doses. Phase I clinical pharmacology studies demonstrated that dapoxetine did not prolong the QT/QTc interval and had neither clinically significant electrocardiographic effects nor evidence of delayed repolarization or conduction effects, with dosing up to 4-fold greater than the maximum recommended dosage. Phase III clinical studies of dapoxetine in men with PE indicated that dapoxetine was generally safe and well tolerated with the dosing regimens used (30 mg and 60 mg as required). Events of syncope were reported during the clinical development program, with the majority occurring during study visits (on site) on day 1 following administration of the first dose when various procedures (e.g. orthostatic maneuvers, venipunctures) were performed, suggesting that the procedures contributed to the incidence of syncope. This was consistent with previous reports showing that these and similar factors contribute to or trigger vasovagal syncope. Findings of the dapoxetine development program demonstrate that dapoxetine is associated with vasovagal-mediated (neurocardiogenic) syncope. No other associated significant cardiovascular adverse events were identified.
Asunto(s)
Bencilaminas/efectos adversos , Sistema Cardiovascular/efectos de los fármacos , Naftalenos/efectos adversos , Inhibidores Selectivos de la Recaptación de Serotonina/efectos adversos , Animales , Ensayos Clínicos como Asunto , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Humanos , Síncope Vasovagal/inducido químicamenteRESUMEN
Oral sodium phosphate (NaP) solution is used globally as a bowel preparation for colonoscopy, surgery and medical-imaging (Balaban 2008). We present a case of a patient who suffered sudden hypotensive syncope and iatrogenic mandibular fractures within an hour of ingesting a NaP solution. We discuss the uses of these medicines and highlight the need to warn patients of possible adverse side effects to avoid patient harm and subsequent litigation.